RADEK SKODA to Adult
This is a "connection" page, showing publications RADEK SKODA has written about Adult.
Connection Strength
0.296
-
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
Score: 0.026
-
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009 Oct; 94(10):1368-74.
Score: 0.019
-
Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
Score: 0.018
-
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
Score: 0.018
-
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
Score: 0.018
-
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica. 2008 May; 93(5):706-14.
Score: 0.017
-
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
Score: 0.015
-
Identification of Hepatic-like EPO as a Cause of Polycythemia. N Engl J Med. 2025 May 01; 392(17):1684-1697.
Score: 0.014
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
Score: 0.014
-
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025 May; 39(5):1135-1145.
Score: 0.014
-
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022 09 13; 6(17):5171-5183.
Score: 0.012
-
Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol. 2000 Jul; 110(1):104-9.
Score: 0.010
-
Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000 Jun; 79(6):312-8.
Score: 0.010
-
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020 04 30; 135(18):1548-1559.
Score: 0.010
-
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nat Commun. 2019 03 19; 10(1):1252.
Score: 0.009
-
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
Score: 0.009
-
Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. Br J Haematol. 1997 Oct; 99(1):56-7.
Score: 0.008
-
Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol. 2017 Mar; 96(3):393-404.
Score: 0.008
-
Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia. 2017 03; 31(3):759-762.
Score: 0.008
-
Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
Score: 0.008
-
Erythropoietin receptor mutation--a rush of blood to the head? Ann Hematol. 2015 Jul; 94(7):1229-31.
Score: 0.007
-
Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
Score: 0.006
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10; 117(10):2813-6.
Score: 0.005
-
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 01; 111(3):1686-9.
Score: 0.004
-
[Immuneglobin-D-serum level with healthy test persons and patients with diseases of the respiratory tract (author's transl)]. Laryngol Rhinol Otol (Stuttg). 1978 Sep; 57(9):850-6.
Score: 0.002
-
The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol. 1998 Sep; 102(5):1341-3.
Score: 0.002